Solid Biosciences
Update in progressSLDB (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Solid Biosciences develops therapies for neuromuscular and cardiac diseases. Its lead candidate, SGT-003, is in Phase 1/2 for Duchenne muscular dystrophy. SGT-212 targets Friedreich’s ataxia in Phase 1b. SGT-501, SGT-601, SGT-401, and SGT-701 are in preclinical or discovery stages for various cardiomyopathies and rare diseases. The company also builds platform technologies, including capsid libraries, genetic regulators, immunomodulation, and multi-gene packaging. Partners include Ultragenyx and universities. Founded 2013, headquartered in Charlestown, MA.
Company score
- Sentiment
- 0.33
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.20
- Governance
- 0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.09
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!